CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to identify protective immune responses against schistosomiasis using samples from controlled human infections and individuals in Uganda. By analyzing multiple antigens and immune responses, the goal is to develop a pre-clinical plan for a vaccine to combat this neglected tropical disease.
Schistosomiasis is a neglected tropical disease afflicting over 200 million people and causing 300,000 deaths in Africa alone.
Whilst infections can be cleared with schistosomocidal drugs, individuals will become rapidly re-infected upon exposure to contaminated water.
Partial immunity only develops naturally only after decades of constant infection, and there is no vaccine.
Previous schistosome vaccine studies have been flawed, due to a lack of understanding of what constitutes a protective imm…
Leiden University Medical Center
ACADEMISCH ZIEKENHUIS LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Janssen Vaccines (f.k.a. Crucell Holland B.V.)
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Netherlands, Leiden
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
